105 results
6-K
EX-99.1
SNY
Sanofi
25 Apr 24
Sales growth of 6.7% at CER and business EPS(1) of €1.78
10:49am
Empowering HCPs and supply chain actors
The specific objectives of this partnership are focused on strengthening advocacy and knowledge about NCDs … , increasing the capacity of healthcare professionals for better management of NCDs and of supply chain actors, while building a sustainable procurement
6-K
EX-99.1
SNY
Sanofi
1 Feb 24
Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology Pipeline
9:45am
and supply chain to the end-life of the product.
Sanofi’s strategy to contribute to the fight against climate change and its impact on people’s health
6-K
EX-99.1
SNY
Sanofi
27 Sep 23
Current report (foreign)
6:06am
to reduce the emissions of our supply chain and minimize the impact our products have on the environment. As we build our road to carbon neutrality by 2030 …
Beyond reducing emissions from operations and its supply chain, Sanofi is focused on decarbonization of healthcare systems and sustainable delivery
6-K
EX-99.3
SNY
Sanofi
20 Jun 23
Current report (foreign)
10:18am
– June 14, 2023 – Sanofi’s Consumer Healthcare Business Unit has today launched a new Open Innovation Portal, allowing the wider supply chain community
6-K
EX-99.2
SNY
Sanofi
20 Jun 23
Current report (foreign)
10:18am
biopharma Supply Chain has proven the ability to predict 80% of low inventory positions, allowing teams to take mitigating actions to secure supply … will present its recently launched Open Innovation Portal, which allows the wider supply chain community to submit their solutions to unmet challenges
SD
tu22 5eq51ye1k3z
30 May 23
Conflict minerals disclosure
11:15am
6-K
EX-99.1
yibxtcq3fq qb6d0o
20 Dec 22
Dupixent® (dupilumab) approved by European Commission as the first and only targeted medicine indicated for prurigo nodularis
6:13am
6-K
EX-99.2
qirxzw01 cxq5dt9e
20 Dec 22
Dupixent® (dupilumab) approved by European Commission as the first and only targeted medicine indicated for prurigo nodularis
6:13am
6-K
EX-99.2
bsecu1v lw8
15 Nov 22
Sanofi and GSK’s next-generation COVID-19 booster vaccine VidPrevtyn® Beta approved by the European Commission
3:01pm
6-K
EX-99.1
8q6fybvm8jh
17 Oct 22
68% of children on a higher dose of Dupixent achieved histological disease remission at week 16
1:35pm
6-K
EX-99.1
sla0 943tbaka6sj
3 Oct 22
Dupixent® (dupilumab) approved by FDA as the first and only treatment indicated for prurigo nodularis
11:24am
6-K
EX-99.2
8ex39bkdxao5ycp7
12 Sep 22
Evolution of the Board of Directors
7:07am
6-K
EX-99.3
3gz8mj4o
12 Sep 22
Evolution of the Board of Directors
7:07am
6-K
EX-99.1
mvtr7ticeptosa az
20 Jul 22
Dupixent® (dupilumab) Phase 3 trial shows positive results in children 1 to 11 years of age with eosinophilic esophagitis
12:38pm
6-K
EX-99.2
8fkdx zbfkrm5xom2
13 Jun 22
FDA approves Dupixent® (dupilumab) as first biologic medicine for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis
2:56pm
6-K
EX-99.1
uq72a
13 Jun 22
FDA approves Dupixent® (dupilumab) as first biologic medicine for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis
2:56pm
6-K
EX-99.2
myc9v79
31 May 22
Update on Cialis® Rx-to-OTC Switch Actual Use Trial
10:56am
6-K
EX-99.1
j7qp hejjo
25 May 22
FDA approves Dupixent® (dupilumab) as first treatment for adults and children aged 12 and older with eosinophilic esophagitis
1:53pm
SD
c9qj3xpb3w 0c56jopt
25 May 22
Conflict minerals disclosure
10:10am
6-K
EX-99.1
9ij2pz29pr4uaw
7 Apr 22
If approved, Dupixent would be the first medicine available in the U.S. indicated to treat eosinophilic esophagitis
3:13pm